Patents Assigned to SUMITOMO PHARMA CO., LTD.
  • Oxo-substituted compound
    Patent number: 11702431
    Abstract: Provided is a novel compound that has an excellent ?-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent ?-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a ?-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and ?-lactam drugs.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: July 18, 2023
    Assignees: Sumitomo Pharma Co., Ltd., THE KITASATO INSTITUTE
    Inventors: Toshio Kanai, Sachiko Koike, Takayuki Fukaya, Shunichiro Uesugi, Shingo Mizushima, Hitoshi Suda, Yuki Mizukami, Yohei Ikuma, Toshiaki Sunazuka, Yoshihiko Noguchi
  • DIHYDROCHROMENE DERIVATIVES
    Publication number: 20230219970
    Abstract: The present invention relates to the compound of formula (I) wherein R1A, R1B, R1C, and R1D are hydrogen atom, etc., R2A and R2B are hydrogen atom, etc., R3A, R3B, R3C, and R3D are hydrogen atom, etc., L is bond, etc., V is C1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.
    Type: Application
    Filed: March 21, 2023
    Publication date: July 13, 2023
    Applicant: Sumitomo Pharma Co., Ltd.
    Inventors: Hitoshi BAN, Seiji KAMIOKA, Yusuke SAWAYAMA, Miki HASHIZUME
  • Fine particle coating (drug-containing hollow particle and method for manufacturing same)
    Patent number: 11696895
    Abstract: Provided is a manufacturing method of particles coated with coatable microparticles. The method is a manufacturing method of particles coated with coatable microparticles, comprising the step of adding the coatable microparticles to an inner core comprising a component of interest and a macromolecule, and, while rolling the mixture, coating the mixture while spraying a solvent that can dissolve the macromolecule, wherein the particles coated with the coatable microparticles are coated, component of interest-containing hollow particles.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: July 11, 2023
    Assignee: Sumitomo Pharma Co., Ltd.
    Inventors: Takumi Asada, Mitsuaki Kobiki
  • PROCESS FOR PREPARING SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES
    Publication number: 20230210850
    Abstract: A process for preparing a compound of Formula (1a): or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 13, 2023
    Publication date: July 6, 2023
    Applicant: Sumitomo Pharma Co., Ltd.
    Inventors: Yohei IKUMA, Kengo TOJO, Ryo FUKAZAWA, Shuji MASUMOTO
  • BENZISOXAZOLE DERIVATIVE
    Publication number: 20230202991
    Abstract: The present invention relates to a medicament for treating various nervous system diseases or psychiatric diseases, comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein R1 is hydrogen, etc., R2 is halogen, etc., R3, R4, R5, and R6 are hydrogen, etc.
    Type: Application
    Filed: July 6, 2021
    Publication date: June 29, 2023
    Applicant: Sumitomo Pharma Co., Ltd.
    Inventors: Tomoyuki TANAKA, Yoshiaki ISOBE, Hiroyuki KITANO, Hiroaki TANAKA, Shun NARAI
  • Cell aggregate including retinal tissue and production method therefor
    Patent number: 11684698
    Abstract: A sphere-like cell aggregate according to one embodiment of the present invention comprises: a core part containing neural retina; and a covering part continuously or discontinuously covering at least a portion of a surface of the core part.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: June 27, 2023
    Assignees: Riken, Sumitomo Pharma Co., Ltd.
    Inventors: Masayo Takahashi, Michiko Mandai, Suguru Yamasaki
  • PHARMACEUTICAL COMPOSITION FOR TREATING CANCER
    Publication number: 20230183316
    Abstract: The present disclosure includes a pharmaceutical composition for treating a cancer in an HLA-A*02:07, HLA-A*03:01, HLA-B*15:01, or HLA-B*27:05-positive subject comprising a WT1-derived cancer antigen peptide or a peptide conjugate containing the peptide.
    Type: Application
    Filed: May 11, 2021
    Publication date: June 15, 2023
    Applicants: SUMITOMO PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventors: Masashi GOTO, Natsuko SUGINOBE, Megumi NAKAMURA
  • THREE-DIMENSIONAL COGNITIVE ABILITY EVALUATION SYSTEM
    Publication number: 20230172527
    Abstract: There are provided a system, an apparatus, a program, and a method for enabling objective evaluation of a three-dimensional cognitive ability through quantification. A three-dimensional cognitive ability of a measurement target person is evaluated by acquiring a position of a moving object, the position enabling identification of a distance between the moving object and the measurement target person, by receiving input of an active response of the measurement target person taken in response to a three-dimensional position of the object recognized by the measurement target person, and by determining whether the position of the object that is acquired and the response that is input correctly match.
    Type: Application
    Filed: May 7, 2021
    Publication date: June 8, 2023
    Applicant: Sumitomo Pharma Co., Ltd.
    Inventors: Yasushi OCHIAI, Kazuki KASAI
  • MANAGEMENT OF PSYCHIATRIC OR MENTAL CONDITIONS USING DIGITAL OR AUGMENTED REALITY WITH PERSONALIZED EXPOSURE PROGRESSION
    Publication number: 20230170075
    Abstract: Systems and methods for implementing an exposure progression that improves an ability of a subject to manage a psychiatric or mental condition of the subject are provided. An exposure progression includes a plurality of categories in a hierarchical order. Each category is associated with one or more experiences, and each experience is associated with a digital reality scene that manifests a challenge. In some embodiments, the hierarchical order is generated or modified dynamically based at least in part on the level of success that a subject has had in one or more challenges, producing an exposure progression that it not only tailored to each subject but also with personalized timing and/or nature of the exposure practice.
    Type: Application
    Filed: December 1, 2022
    Publication date: June 1, 2023
    Applicants: BehaVR, Inc., Sumitomo Pharma Co., Ltd.
    Inventors: Aprilia Alam, Brandon Hedges, Christina Zaluski, Eleanor Anderson, Georgia Mitsi, Joyce Tsai, Morgan Taylor, Risa Weisberg, Sarah Zadd, Todd Grinnell
  • 1,4-disubstituted imidazole derivative
    Patent number: 11661397
    Abstract: The present invention provides a 1,4-disubstituted imidazole derivative of formula (1?) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6 alkyl group, etc.; ring Q2 is 5- to 10-membered heteroaryl group, etc.; W3 is optionally-substituted C1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R4 is independently halogen atom, optionally-substituted C1-6 alkyl group, etc.; R5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: May 30, 2023
    Assignee: Sumitomo Pharma Co., Ltd.
    Inventors: Hitoshi Ban, Manabu Kusagi, Shingo Tojo, Futoshi Hasegawa, Miki Hashizume
  • THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE
    Publication number: 20230149357
    Abstract: The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson’s disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson’s disease and/or an effect of preventing the recurrence of the same.
    Type: Application
    Filed: December 28, 2022
    Publication date: May 18, 2023
    Applicant: Sumitomo Pharma Co., Ltd.
    Inventors: Taro KATO, Satoko SHIMIZU
  • Method for producing retinal pigment epithelial cells
    Patent number: 11649432
    Abstract: The present invention provides a method for more efficiently producing retinal pigment epithelial cells from pluripotent stem cells. The method of the present invention for producing retinal pigment epithelial cells includes the following steps: (1) a first step for culturing a pluripotent stem cell in a medium comprising an FGF receptor inhibitor and/or an MEK inhibitor for a period of not more than 30 days, and (2) a second step for culturing the cell obtained in the first step in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor to form a retinal pigment epithelial cell.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 16, 2023
    Assignees: SUMITOMO PHARMA CO., LTD., HEALIOS K.K.
    Inventors: Satoshi Ando, Takao Kuroda
  • Dihydrochromene derivatives
    Patent number: 11639357
    Abstract: The present invention relates to the compound of formula (I) wherein R1A, R1B, R1C, and R1D are hydrogen atom, etc., R2A and R2B are hydrogen atom, etc., R3A, R3B, R3C, and R3D are hydrogen atom, etc., L is bond, etc., V is C1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: May 2, 2023
    Assignee: Sumitomo Pharma Co., Ltd.
    Inventors: Hitoshi Ban, Seiji Kamioka, Yusuke Sawayama, Miki Hashizume
  • Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor
    Patent number: 11633395
    Abstract: Provided are a compound that is useful for the prevention of and/or as a treatment agent for a disease in which a group II mGlu receptor is involved; and a medical application of said compound. Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 22, 2018
    Date of Patent: April 25, 2023
    Assignee: SUMITOMO PHARMA CO., LTD.
    Inventors: Yohei Ikuma, Kengo Tojo, Ryo Fukazawa, Shuji Masumoto
  • Therapeutic drug for motor complications in Parkinson's disease
    Patent number: 11628169
    Abstract: The present disclosure provides a therapeutic drug that is useful for the treatment of motor fluctuations (e.g., wearing-off) in Parkinson's disease. In particular, the present disclosure provides a composition and method for treating, improving, suppressing the progression, or preventing motor complications in Parkinson's disease, especially motor fluctuation, comprising tandospirone or a pharmaceutically acceptable salt thereof, wherein the tandospirone or a pharmaceutically acceptable salt thereof is parenterally administered.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: April 18, 2023
    Assignee: SUMITOMO PHARMA CO., LTD.
    Inventors: Mitsumasa Kurita, Yuki Ikeda, Mitsuhiro Nakato
  • THERAPEUTIC AGENT FOR TAUOPATHIES
    Publication number: 20230109839
    Abstract: The present invention is to provide a medicament for treating and/or preventing tauopathy by activating the voltage-gated sodium channel (Nav). The present invention relates to a medicament for treating and/or preventing tauopathy, comprising a Nav activator as an active ingredient.
    Type: Application
    Filed: January 6, 2021
    Publication date: April 13, 2023
    Applicant: SUMITOMO PHARMA CO., LTD.
    Inventors: Kazuaki SAMPEI, Takeo ISHIYAMA, Atsushi IKEDA, Taizo ISHIKAWA, Makoto HIGUCHI, Hiroyuki TAKUWA, Yuhei TAKADO
  • Method for producing retinal pigment epithelial cells
    Patent number: 11618883
    Abstract: The present invention provides a production method of a retinal pigment epithelial cell containing the following steps: (1) a first step for culturing a pluripotent stem cell in a medium containing at least one kind selected from the group consisting of an FGF receptor inhibitor and an MEK inhibitor for a period of not more than 30 days, and (2) a second step for culturing the cell obtained in the first step in a medium containing at least one kind selected from the group consisting of a Rho signal transduction pathway inhibitor and an apoptosis inhibitor to form a retinal pigment epithelial cell. The method can produce retinal pigment epithelial cells from pluripotent stem cells more efficiently and conveniently.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: April 4, 2023
    Assignees: SUMITOMO PHARMA CO., LTD., HEALIOS K.K.
    Inventor: Takao Kuroda
  • RI-LABELED HUMANIZED ANTIBODY
    Publication number: 20230094773
    Abstract: The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits ? particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.
    Type: Application
    Filed: May 26, 2022
    Publication date: March 30, 2023
    Applicants: NIHON MEDI-PHYSICS CO., LTD., SUMITOMO PHARMA CO., LTD.
    Inventors: Norihito Nakata, Nobuya Kobashi, Yoshinari Shoyama, Mitsuhiro Matono, Yasushi Ochiai, Takayuki Murakami
  • Method for Culturing Hematopoietic Stem Cells
    Publication number: 20230094952
    Abstract: An object of the present invention is to provide a method for culturing one or more hematopoietic stem cells applicable to hematopoietic stem cell transplantation, and a method for producing such one or more hematopoietic stem cells.
    Type: Application
    Filed: December 25, 2020
    Publication date: March 30, 2023
    Applicants: Sumitomo Pharma Co., Ltd., NextGeM Inc.
    Inventors: Atsushi Nakane, Hidetaka Nagata, Shigehiro Asano, Masanori Miyanishi, Hitoshi Suda, Yusuke Shioda
  • OXADIAZOLE DERIVATIVE
    Publication number: 20230092498
    Abstract: The present invention relates to a compound of formula (1) wherein Q1 is halogen atom, Q2 is hydrogen atom, etc., X, Y, and Z are nitrogen atom or oxygen atom, and R1 has a given structure, or a pharmaceutically acceptable salt thereof, and a medicament comprising the compound for treating and/or preventing a disease such as epilepsy.
    Type: Application
    Filed: September 16, 2022
    Publication date: March 23, 2023
    Applicant: Sumitomo Pharma Co., Ltd.
    Inventors: Yoshiaki ISOBE, Tomoyuki TANAKA, Hirotaka MIYACHI